MedPath

Sanofi

Sanofi logo
🇫🇷France
Ownership
Public
Employees
87.9K
Market Cap
$141.3B
Website
http://www.sanofi.com
Introduction

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

pharmabiz.com
·

Sanofi, RadioMedix & Orano Med enter licensing agreement on next-generation radioligand

Sanofi, RadioMedix, and Orano Med collaborate on AlphaMedix, a targeted alpha therapy for neuroendocrine tumors, granted Breakthrough Therapy Designation by the FDA. Sanofi to commercialize, Orano Med to manufacture, with an upfront payment of €100 million and potential milestones up to €220 million.

Sanofi signs radioligand therapy licensing deal for rare cancers

Sanofi signs exclusive licensing agreement with RadioMedix and Orano Med to advance AlphaMedix, a radioligand therapy for rare cancers, with a €100m upfront payment and potential €220m in sales-based milestones.
pharmexec.com
·

Dupixent Demonstrates Reducing Symptoms of Chronic Spontaneous Urticaria

Dupixent (dupilumab) showed significant potential in treating chronic spontaneous urticaria (CSU) in biologic-naïve patients unresponsive to antihistamines, reducing itch and urticaria activity scores by 50% compared to placebo in the LIBERTY-CUPID Study C. The safety profile of Dupixent remained consistent with previous findings, and the study results are expected to be submitted to the FDA by the end of the year.
biopharmadive.com
·

Fulcrum shares collapse as Sanofi-partnered muscular dystrophy drug fails key test

Fulcrum Therapeutics' experimental drug losmapimod failed a Phase 3 trial for muscular dystrophy FSHD, leading to suspension of its development. Despite positive signs in previous tests, losmapimod missed its main objective and secondary goals. Fulcrum's shares dropped 60%, and the company will focus on its sickle cell disease treatment, expecting Phase 1 data next year. The FDA previously suspended testing of the sickle cell therapy for six months.
investing.com
·

Earnings call: Innate Pharma reports progress in oncology pipeline

Innate Pharma reported H1 2024 financials and clinical updates, including $12.3M revenue, $38.7M operating expenses, and $102.1M cash reserves. Lacutamab, an orphan drug, showed promising results in trials and received FDA designation. The ANKET platform advanced with SAR443579 in Phase 2 and IPH6501 in clinical trials. IPH45, an ADC targeting Nectin-4, is moving to Phase 1. The company aims to address unmet oncology needs and expects clinical data in the coming years.
pmlive.com
·

Sanofi/Regeneron's Dupixent approved by MHRA to treat uncontrolled COPD

Sanofi and Regeneron’s Dupixent approved by MHRA as add-on treatment for uncontrolled COPD in UK, reducing exacerbations and improving lung function.
patientcareonline.com
·

GSK mRNA Flu Vaccine Candidate Delivers Favorable Topline Phase 2 Findings, Ready for Phase 3

GSK's phase 2 data for its seasonal influenza mRNA vaccine, GSK4382276A, showed robust immune responses against A and B strains in older and younger adults, supporting progression to phase 3 trials. The vaccine demonstrated acceptable safety and reactogenicity profiles, aiming to develop a best-in-class vaccine for greater protection during flu season.
sanofi.com
·

Sanofi, RadioMedix, and Orano Med announce licensing agreement on next ...

Sanofi, RadioMedix, and Orano Med collaborate on AlphaMedix™, a lead-212 radioligand therapy for neuroendocrine tumors, granted Breakthrough Therapy Designation by the FDA.
whbl.com
·

Moderna expects up to $3.5 billion in 2025 sales

Moderna forecasts $2.5-$3.5B in 2024 sales, with 25% annual revenue growth from 2026-2028 driven by new product launches. The company anticipates 10 new product approvals by 2027, with meaningful revenue from 2028. Moderna plans to expand RSV vaccine approval to high-risk adults under 60 and focus on a COVID-influenza combination shot.

Phase III CSU treatment trial meets endpoints

Sanofi's Phase III LIBERTY-CUPID Study C of Dupixent in chronic spontaneous urticaria (CSU) met primary and key secondary endpoints. The study, focusing on biologic-naïve patients with uncontrolled CSU on antihistamines, showed Dupixent reduced itch severity by 8.64 points vs. 6.10 points with placebo at 24 weeks. Additionally, 30% of Dupixent patients reported no urticaria, compared to 18% on placebo. Safety results aligned with Dupixent's known profile, with treatment-emergent adverse events at 53% for both Dupixent and placebo.
© Copyright 2025. All Rights Reserved by MedPath